Javascript verkar inte påslaget? - Vissa delar av Lunds universitets webbplats fungerar inte optimalt utan javascript, kontrollera din webbläsares inställningar.
Du är här

Humoral immunity targeting site I of antigenic domain 2 of glycoprotein B upon immunization with different cytomegalovirus candidate vaccines.

Publiceringsår: 2007
Språk: Engelska
Sidor: 41-46
Publikation/Tidskrift/Serie: Vaccine
Volym: 26
Nummer: 1
Dokumenttyp: Artikel i tidskrift
Förlag: Elsevier


Glycoprotein B (gB) is a major component in several vaccines that are under development for prevention of disease by cytomegalovirus. It contains multiple determinants that are targets for neutralizing antibodies. One of them is site I of antigenic domain 2 (AD-2). The epitope, defined by short peptides, is quite conserved between different isolates. However, it is poorly immunogenic in natural infection. In this study we investigated the extent to which different vaccines, attenuated live Towne vaccine with or without priming with a canarypox virus coding for gB, or a recombinant gB vaccine adjuvanted with MF59, induced antibodies to this epitope. As in natural infection only a fraction of all subjects developed antibody responses against site I of AD-2 following vaccination. We suggest that strategies that enhance immunogenicity of this epitope will improve vaccine efficacy.


  • Immunology in the medical area
  • Viral/blood
  • Cytomegalovirus Vaccines/immunology
  • Epitope Mapping
  • Humans
  • Immunization
  • Protein Structure
  • Antibodies
  • Tertiary
  • Vaccines
  • Attenuated/immunology
  • Synthetic/immunology
  • Viral Envelope Proteins/chemistry
  • Viral Envelope Proteins/immunology


  • ISSN: 1873-2518

Box 117, 221 00 LUND
Telefon 046-222 00 00 (växel)
Telefax 046-222 47 20
lu [at] lu [dot] se

Fakturaadress: Box 188, 221 00 LUND
Organisationsnummer: 202100-3211
Om webbplatsen